Cannabinoids

A recent study targeting mild to moderate anxiety disorders showed that oral CBD can be a safe, effective treatment option.

This article provides an analysis of current regulations and proposed changes that could impact the hemp industry.

Missouri’s Department of Health and Senior Services is on track to “embargo and condemn” products that contain intoxicating cannabinoids starting September 1, 2024 in accordance to an executive order signed by the state’s governor, Michael L. Parsons.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

This presentation provided a comprehensive overview of cannabigerol (CBG), highlighting two studies on its effects on anxiety, stress, and pain.

The discussion surrounding intoxicating the manufacture and sale of hemp-derived cannabinoids continues with more proposals and challenges.

This article will cover what the differences are between hemp and cannabis, the products that are on the market today, and why it is important to know where your product is coming from.

This review highlights an in-silico assessment of the binding interactions of pro-drug moiety analogs and an importance in identifying potential issues that would need further testing to ensure safety for consumers such as the hERG values which are pertinent in the pharmaceutical fields in whether or not drugs can be safe to use.

This month’s Healer webinar provided a deep dive into six studies on cannabis for various conditions.

The cannabis industry continues to demand high purity cannabis extracts at a low cost. Here, we investigate the opportunities and challenges as manufacturers implement automation and scaling up production.

As markets mature, manufacturing terpene blends have become a new art form and a differentiating factor for potential therapeutic applications. Here, we dive deeper into the insights of terpene formulation considerations.

Two cannabinoids were shown to help with both pain relief and healing of fractures.

Both the Senate and the House have drafted bills restricting the sale of hemp-derived products.

A bill to ban unregulated tetrahydrocannabinol (THC) products was approved by a House committee.

On January 31, 2024, the GMP Collective presented the seventeenth episode in their ongoing webinar series, When Things Go Wrong.

A recent study explored cannabinoids as an alternative treatment for neuropathic pain from spinal cord injuries.

A recent study examined adult use of four cannabinoids within the past year.

A study involving cannabigerol (CBG) injections in mice tested the effectiveness in pain reduction.

Brandy Young, PhD, the CEO and Founder of Certainty Analytical Labs in New York, discussed her work in compliance testing for cannabis products at EAS 2023.

This article explores chromatographic separation techniques for the efficient purification of cannabinoids along with the benefits and drawbacks of these separation methods.

Don't miss Part I of this Noid Factoid from Nick Jikomes, PhD, the Director of Science & Innovation at Leafly.

The webinar "Cannabis and Dementia: Unlocking the Potential" was held on June 14, 2023, and featured four panelists’ experiences treating dementia symptoms with cannabis.

Within the next few weeks, France will become the latest country to ban the substance hexahydrocannabinol (HHC).

This article provides insights into the opportunities involving the genetic modification of cannabis.

Searching for purer, minor cannabinoids is the goal of new extraction research as extractors dig deeper into the diversity of the plant.

The current challenges and future perspectives of the purification of cannabinoids from cannabis extracts are presented in this review article.

The effects of worms consuming cannabis were researched in a experiment showing that that they got the munchies and craved junk food.

To help clinicians and patients navigate cannabinoid-based medications (CBM), Cannabis and Cannabinoid Research published guidelines based on reviews of studies on CBM and chronic pain.

When you think of cannabis, you probably don’t think of horses or the potential medicinal benefit to animals. However, the cannabinoids found in cannabis have been shown to provide similar benefits in animals that are noted with human patients. In this interview, Emma Davis, founder of Mikko’s Choice, delves into how some cannabinoids—such as tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabinolic acid (THCA)—have provided medicinal benefits to horses. Davis also discusses her mustang, Mikko, who inspired her to launch her own cannabis and hemp product brand.

On February 13, 2023, the US Drug Enforcement Administration (DEA) declared in a letter that the cannabinoids delta-8 and -9 THCO are both considered controlled substances due to their chemical structures.